Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review
Nicola LongoMarco CapeceGiuseppe CelentanoRoberto La RoccaGianluigi CalifanoClaudia Collà RuvoloCarlo BuonerbaFabio EspositoLuigi NapolitanoFrancesco MangiapiaFerdinando FuscoVincenzo MironeMassimiliano Creta
11
Citation
53
Reference
10
Related Paper
Citation Trend
Abstract:
A high percentage of patients with metastatic renal cell carcinoma (mRCC) require a second-line option. We aimed to summarize available evidences about the clinicopathological profile of mRCC patients who receive a second-line therapy. A systematic review was performed in August 2020. We included papers that met the following criteria: original research; English language; human studies; enrolling mRCC patients entering a second-line therapy. Twenty-nine studies enrolling 7650 patients (73.5% male, mean age: 55 to 70 years) were included. Clear cell histology was reported in 74.4% to 100% of cases. Tyrosine kinase inhibitors, immunotherapy, bevacizumab, mTOR inhibitors, and chemotherapy were adopted as first line option in 68.5%, 29.2%, 2.9%, 0.6%, and 0.2% of patients, respectively. Discontinuation of first-line therapy was due to progression and toxicity in 18.4% to 100% and in 17% to 48.8% of patients, respectively. Eastern Cooperative Oncology Group performance status score was 0 or 1 in most cases. Most prevalent prognostic categories according to the International Metastatic RCC Database Consortium and Memorial Sloan–Kettering Cancer Centre score were intermediate and good. About 77.8% of patients harboured ≥2 metastatic sites. In conclusion, patients who enter a second-line therapy are heterogeneous in terms of a clinical-pathological profile. Tailoring of second-line treatment strategies is strongly advocated.Keywords:
Discontinuation
Targeted Therapy
Targeted therapy has favorably changed the standard of care for patients with advanced renal cell carcinoma. However, combinations of targeted therapy have been characterized by excessive toxicity, as exemplified in the report by Molina et al in this issue.
Targeted Therapy
Cite
Citations (8)
This study aimed to investigate expression level of FOXC2 and its relationship to clinical pathological features of renal cell carcinoma (RCC).The expression levels of FOXC2 in RCC tissues and normal renal tissues (62 samples, respectively) were detected by immunohistochemistry and PCR Array. Statistics analyses were done with SPSS to compare the differences between RCC tissues and normal renal tissue, and to explore the relationship between the expression level of FOXC2 and the clinical pathological features of RCC.Expression level of FOXC2 in RCC tissues was significantly higher than in normal renal tissues, and other related cancer genes also highly expressed in RCC tissues. FOXC2 expression was positively associated with clinical stage and pathological grade (P < 0.05), but not significantly related to the gender and age (P > 0.05).The expression of FOXC2 in renal cell carcinoma was significantly higher than that in normal renal tissues. It is suggested that FOXC2 might play a crucial role in the occurrence and development of RCC and could be an important prognostic indicator for clinical therapy.
Cite
Citations (5)
Renal cell carcinoma(RCC)is one of the most common malignant urinary tumors.Molecular targeted therapy is a way that can inhibit tumor growth by specific cellular pathway.Also,it is better than traditional cytokine therapy.However,effective ways for determing the outcome of targeted therapy are still insufficient.In this review,prognostic related factors of targeted therapy in renal cell carcinoma were summarized referred to the current study.
Targeted Therapy
Cite
Citations (0)
Renal cell carcinoma(RCC) is a highly malignant tumor in the urinary system.Radical surgery is the main therapeutic method for the early stage of RCC,but the therapeutic efficacy in advanced or metastatic RCC is not satisfied.As the development of molecular biology,the targeted therapy against RCC achieves a new progress.This review aims to make a summary about molecular basis and new progress of targeted therapy in recent years on advanced clear cell and non-clear cell RCC.
Targeted Therapy
Cite
Citations (0)
Purpose of review A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma. Recent findings New phase II and phase III clinical data on both Food and Drug Administration approved and investigational targeted agents are now available, widening the choice of therapies in the treatment of metastatic renal cell carcinoma. Summary We provide a review of the data to facilitate effective evidence-based clinical practice and also aim to give a perspective for future clinical and translational research in renal cell carcinoma.
Targeted Therapy
Translational Research
Cite
Citations (14)
Targeted Therapy
Second line
Cite
Citations (0)
Renal cell carcinoma (RCC) accounts for approximately 4% of all primary cancers diagnosed in the United States with an estimated 13,000 deaths in 2010. Metastatic disease is the initial presentation in approximately 30% of the patients. Until 2006, immunotherapy with Interferon-? and Interleukin-2 represented the primary treatment of advanced RCC but better understanding of the pathogenesis and molecular biology of RCC paved the way for targeted molecular therapies. Six molecular targeted agents have been approved for the treatment of metastatic renal cell carcinoma (mRCC). This review summarizes the approved targeted agents, their toxicities and practical insights into the treatment of mRCC.
Targeted Therapy
Cite
Citations (0)
Targeted Therapy
Primary tumor
Systemic therapy
Kidney cancer
Cite
Citations (0)
Renal cell carcinoma is the most common malignant disease which is insensitive to radiotherapy,chemotherapy and radical surgery that was the main treatment for kidney cancer in the past. Since sorafenib was as the first one of the advent of targeted drugs for metastatic renal cell carcinoma, more and more targeted drugs have been researched and applied in clinic and achieved great success. This article introduces the clinical efficacy, adverse reactions, drug-drug combination and sequential use of targeted therapy for the renal cell carcinoma.
Targeted Therapy
Kidney cancer
Cite
Citations (0)
Targeted Therapy
Kidney cancer
Cite
Citations (0)